As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Avidity Biosciences, Inc. The largest reported stake is The Vanguard Group's, at 9.57%. 15 filings are on record since August 7, 2025 (Schedule 13G/A, October 30, 2025).
Sell to companies like Avidity Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: RA Capital Management, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: T. Rowe Price Associates, Inc. · Percent: 0.1% · SCHEDULE 13G/A
- · Holder: Avoro Capital Advisors LLC · Percent: 5.54% · SCHEDULE 13G/A
- · Holder: Janus Henderson Group Plc · Percent: 4.6% · SCHEDULE 13G/A
- · Holder: Wellington Management Group LLP · Percent: 0.5% · SCHEDULE 13G/A
Avidity Biosciences, Inc. has 15 Schedule 13D or 13G filings on record since 2025-08-07. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The Vanguard Group | 9.57% | 13,219,759 | SCHEDULE 13G/A, 2025-10-30 | 2025-09-30 |
| BlackRock, Inc. | 6.4% | 8,631,771 | SCHEDULE 13G/A, 2025-10-17 | 2025-09-30 |
| Avoro Capital Advisors LLC | 5.54% | 8,515,792 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Janus Henderson Group Plc | 4.6% | 6,939,503 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| RTW Investments, LP | 3.1% | 4,686,110 | SCHEDULE 13D/A, 2025-10-29 | 2025-10-27 |
| Fmr LLC | 2.1% | 2,958,712 | SCHEDULE 13G/A, 2025-11-07 | 2025-10-31 |
| Wellington Management Group LLP | 0.5% | 723,118 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-31 |
| T. Rowe Price Associates, Inc. | 0.1% | 142,888 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| RA Capital Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Avidity Biosciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Avidity Biosciences, Inc. and the records around it.
Avidity Biosciences, Inc. elsewhere on the record
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Avidity Biosciences, Inc.
Get an email when Avidity Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Avidity Biosciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Avidity Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avidity Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Janus Henderson Group Plc | 10.1% | SCHEDULE 13G/A |
| 2025-10-17 | BlackRock, Inc. | 6.4% | SCHEDULE 13G/A |
| 2025-10-29 | RTW Investments, LP | 3.1% | SCHEDULE 13D/A |
| 2025-10-30 | The Vanguard Group | 9.57% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2025-11-07 | Fmr LLC | 2.1% | SCHEDULE 13G/A |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 7.1% | SCHEDULE 13G/A |
| 2025-11-14 | RA Capital Management, L.P. | 5.9% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 10.7% | SCHEDULE 13G/A |
| 2025-12-05 | Janus Henderson Group Plc | 5.5% | SCHEDULE 13G/A |
| 2026-02-10 | Wellington Management Group LLP | 0.5% | SCHEDULE 13G/A |
| 2026-02-17 | T. Rowe Price Associates, Inc. | 0.1% | SCHEDULE 13G/A |
| 2026-02-17 | Avoro Capital Advisors LLC | 5.54% | SCHEDULE 13G/A |
| 2026-02-17 | Janus Henderson Group Plc | 4.6% | SCHEDULE 13G/A |
| 2026-05-15 | RA Capital Management, L.P. | 0% | SCHEDULE 13G/A |
Questions about who owns Avidity Biosciences, Inc.
Who owns Avidity Biosciences, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Avidity Biosciences, Inc.: The Vanguard Group (9.57%, Schedule 13G/A, filed 2025-10-30), BlackRock, Inc. (6.4%, Schedule 13G/A, filed 2025-10-17) and Avoro Capital Advisors LLC (5.54%, Schedule 13G/A, filed 2026-02-17).
Who are the largest shareholders of Avidity Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Avidity Biosciences, Inc. on this page are The Vanguard Group (9.57%), BlackRock, Inc. (6.4%) and Avoro Capital Advisors LLC (5.54%).
When did The Vanguard Group buy into Avidity Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from The Vanguard Group on this page is the Schedule 13G/A, filed 2025-10-30, reporting 9.57%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Avidity Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.